DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis
NYSE:DOCS - New York Stock Exchange, Inc. - US26622P1075 - Common Stock - Currency: USD
We assign a fundamental rating of 7 out of 10 to DOCS. DOCS was compared to 39 industry peers in the Health Care Technology industry. DOCS scores excellent points on both the profitability and health parts. This is a solid base for a good stock. DOCS is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings could make DOCS a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year DOCS was profitable.
In the past year DOCS had a positive cash flow from operations.
Each year in the past 5 years DOCS has been profitable.
Each year in the past 5 years DOCS had a positive operating cash flow.
1.2 Ratios
DOCS's Return On Assets of 17.18% is amongst the best of the industry. DOCS outperforms 97.30% of its industry peers.
The Return On Equity of DOCS (19.53%) is better than 97.30% of its industry peers.
Looking at the Return On Invested Capital, with a value of 17.38%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for DOCS is significantly above the industry average of 6.44%.
The 3 year average ROIC (12.02%) for DOCS is below the current ROIC(17.38%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.18% | ||
| ROE | 19.53% | ||
| ROIC | 17.38% |
ROA(3y)12.35%
ROA(5y)10.68%
ROE(3y)14.41%
ROE(5y)14.17%
ROIC(3y)12.02%
ROIC(5y)17.46%
1.3 Margins
DOCS's Profit Margin of 36.60% is amongst the best of the industry. DOCS outperforms 97.30% of its industry peers.
In the last couple of years the Profit Margin of DOCS has grown nicely.
DOCS has a better Operating Margin (40.58%) than 100.00% of its industry peers.
In the last couple of years the Operating Margin of DOCS has grown nicely.
The Gross Margin of DOCS (90.19%) is better than 97.30% of its industry peers.
In the last couple of years the Gross Margin of DOCS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.58% | ||
| PM (TTM) | 36.6% | ||
| GM | 90.19% |
OM growth 3Y11.94%
OM growth 5Y35.03%
PM growth 3Y43.8%
PM growth 5Y113.48%
GM growth 3Y1.71%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
DOCS has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for DOCS has been reduced compared to 1 year ago.
DOCS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 62.07 indicates that DOCS is not in any danger for bankruptcy at the moment.
The Altman-Z score of DOCS (62.07) is better than 100.00% of its industry peers.
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 62.07 |
ROIC/WACC1.71
WACC10.18%
2.3 Liquidity
DOCS has a Current Ratio of 8.74. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of DOCS (8.74) is better than 100.00% of its industry peers.
A Quick Ratio of 8.74 indicates that DOCS has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 8.74, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.74 | ||
| Quick Ratio | 8.74 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 42.22% over the past year.
The Earnings Per Share has been growing by 81.49% on average over the past years. This is a very strong growth
Looking at the last year, DOCS shows a quite strong growth in Revenue. The Revenue has grown by 17.46% in the last year.
The Revenue has been growing by 40.87% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)42.22%
EPS 3Y81.49%
EPS 5YN/A
EPS Q2Q%55.17%
Revenue 1Y (TTM)17.46%
Revenue growth 3Y31.96%
Revenue growth 5Y40.87%
Sales Q2Q%24.63%
3.2 Future
The Earnings Per Share is expected to grow by 13.57% on average over the next years. This is quite good.
DOCS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.03% yearly.
EPS Next Y38.7%
EPS Next 2Y23.02%
EPS Next 3Y19.68%
EPS Next 5Y13.57%
Revenue Next Year13.96%
Revenue Next 2Y12.18%
Revenue Next 3Y11.51%
Revenue Next 5Y11.03%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 56.54, DOCS can be considered very expensive at the moment.
75.68% of the companies in the same industry are more expensive than DOCS, based on the Price/Earnings ratio.
DOCS's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 29.63.
DOCS is valuated quite expensively with a Price/Forward Earnings ratio of 50.34.
70.27% of the companies in the same industry are more expensive than DOCS, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.68. DOCS is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 56.54 | ||
| Fwd PE | 50.34 |
4.2 Price Multiples
62.16% of the companies in the same industry are more expensive than DOCS, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, DOCS is valued a bit cheaper than 62.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 58.51 | ||
| EV/EBITDA | 53.71 |
4.3 Compensation for Growth
DOCS's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of DOCS may justify a higher PE ratio.
DOCS's earnings are expected to grow with 19.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.46
PEG (5Y)N/A
EPS Next 2Y23.02%
EPS Next 3Y19.68%
5. Dividend
5.1 Amount
No dividends for DOCS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
72.37
-2.63 (-3.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners94.84%
Inst Owner Change0.55%
Ins Owners2.6%
Ins Owner Change-0.83%
Market Cap13.58B
Analysts72.31
Price Target56.33 (-22.16%)
Short Float %4.35%
Short Ratio2.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.24%
Min EPS beat(2)15.86%
Max EPS beat(2)30.62%
EPS beat(4)4
Avg EPS beat(4)23.59%
Min EPS beat(4)15.86%
Max EPS beat(4)30.62%
EPS beat(8)8
Avg EPS beat(8)22.02%
EPS beat(12)12
Avg EPS beat(12)23%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)6.83%
Min Revenue beat(2)5.51%
Max Revenue beat(2)8.16%
Revenue beat(4)3
Avg Revenue beat(4)4.17%
Min Revenue beat(4)-0.57%
Max Revenue beat(4)8.16%
Revenue beat(8)5
Avg Revenue beat(8)2.53%
Revenue beat(12)8
Avg Revenue beat(12)1.92%
Revenue beat(16)11
Avg Revenue beat(16)1.76%
PT rev (1m)0%
PT rev (3m)48.39%
EPS NQ rev (1m)20.44%
EPS NQ rev (3m)15.38%
EPS NY rev (1m)13.36%
EPS NY rev (3m)21.92%
Revenue NQ rev (1m)4.43%
Revenue NQ rev (3m)5.69%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)2.8%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 56.54 | ||
| Fwd PE | 50.34 | ||
| P/S | 24.68 | ||
| P/FCF | 58.51 | ||
| P/OCF | 56.88 | ||
| P/B | 13.17 | ||
| P/tB | 14.46 | ||
| EV/EBITDA | 53.71 |
EPS(TTM)1.28
EY1.77%
EPS(NY)1.44
Fwd EY1.99%
FCF(TTM)1.24
FCFY1.71%
OCF(TTM)1.27
OCFY1.76%
SpS2.93
BVpS5.5
TBVpS5
PEG (NY)1.46
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.18% | ||
| ROE | 19.53% | ||
| ROCE | 21.14% | ||
| ROIC | 17.38% | ||
| ROICexc | 86.87% | ||
| ROICexgc | 153.93% | ||
| OM | 40.58% | ||
| PM (TTM) | 36.6% | ||
| GM | 90.19% | ||
| FCFM | 42.18% |
ROA(3y)12.35%
ROA(5y)10.68%
ROE(3y)14.41%
ROE(5y)14.17%
ROIC(3y)12.02%
ROIC(5y)17.46%
ROICexc(3y)87.69%
ROICexc(5y)N/A
ROICexgc(3y)180.49%
ROICexgc(5y)N/A
ROCE(3y)14.62%
ROCE(5y)21.23%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y-48.43%
ROICexc growth 5YN/A
OM growth 3Y11.94%
OM growth 5Y35.03%
PM growth 3Y43.8%
PM growth 5Y113.48%
GM growth 3Y1.71%
GM growth 5Y0.47%
F-Score9
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 64.1% | ||
| Cap/Sales | 1.21% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 102.17% | ||
| Profit Quality | 115.26% | ||
| Current Ratio | 8.74 | ||
| Quick Ratio | 8.74 | ||
| Altman-Z | 62.07 |
F-Score9
WACC10.18%
ROIC/WACC1.71
Cap/Depr(3y)76.9%
Cap/Depr(5y)164.34%
Cap/Sales(3y)1.45%
Cap/Sales(5y)2.04%
Profit Quality(3y)121.74%
Profit Quality(5y)186.38%
High Growth Momentum
Growth
EPS 1Y (TTM)42.22%
EPS 3Y81.49%
EPS 5YN/A
EPS Q2Q%55.17%
EPS Next Y38.7%
EPS Next 2Y23.02%
EPS Next 3Y19.68%
EPS Next 5Y13.57%
Revenue 1Y (TTM)17.46%
Revenue growth 3Y31.96%
Revenue growth 5Y40.87%
Sales Q2Q%24.63%
Revenue Next Year13.96%
Revenue Next 2Y12.18%
Revenue Next 3Y11.51%
Revenue Next 5Y11.03%
EBIT growth 1Y37.19%
EBIT growth 3Y47.72%
EBIT growth 5Y90.21%
EBIT Next Year28.08%
EBIT Next 3Y16.55%
EBIT Next 5Y15.44%
FCF growth 1Y34.38%
FCF growth 3Y31.5%
FCF growth 5Y66.11%
OCF growth 1Y32.62%
OCF growth 3Y30.41%
OCF growth 5Y64.46%